Insider trade

Bolt Biotherapeutics (BOLT): 10% owner bought ~$115K

Coastlands Capital LP, 10% owner at Bolt Biotherapeutics, bought ~$115K of Bolt Biotherapeutics shares.

~$115K
Approx. value · 20K sh @ $5.75
516K
Holds after · shares reported
Traded
Nov 17, 2026
Filed
Nov 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 16, 2026Insider · 3 peopleInsiders: 3 sales (~$16K)
  2. Sep 17, 2026Insider · 3 peopleInsiders: 3 sales (~$48K)
  3. Sep 18, 2026Insider · 3 peopleInsiders: 3 sales (~$65K)
  4. Oct 1, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  5. Oct 23, 2026Company filing · Form 8-K · Material agreement, Agreement endedCompleted buying or selling a business or assets, and changed a top executive or board member (and 6 more items)“Appointment of Director In accordance with the Merger Agreement, on October 23, 2026, effective immediately after the First Effective Time, Dr. Sheila Gujrathi was appointed to the Board as a Class II director of the Board.”
  6. Nov 6, 20265% stakeCoastlands Capital LP reported a passive stake (13G) of 17.5%
  7. Nov 9, 2026Insider · Bought outside the usual window10% owner purchased ~$319K of BOLT shares in the open market
  8. Nov 12, 2026Company filing · Form 8-K · ResultsReported its results
  9. Nov 12, 20265% stakeRenaissance Technologies LLC reported a passive stake (13G) of 4.8%
  10. Nov 16, 2026Insider10% owner purchased ~$195K of BOLT shares in the open market
  11. Nov 17, 2026 · this disclosureInsider10% owner purchased ~$115K of BOLT shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Bolt Biotherapeutics

For Bolt Biotherapeutics, OQRO holds 12 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BOLT page.

Other recent filings by Coastlands Capital LP, 10% owner

The full history of Coastlands Capital LP, 10% owner is on the profile page.

How this filing works

Explore the data

Common questions

Which Bolt Biotherapeutics (BOLT) insider traded, and how much?

Coastlands Capital LP, 10% owner at Bolt Biotherapeutics, bought ~$115K of Bolt Biotherapeutics shares. 20K shares at $5.75, open market.

When did it happen, and when was it made public?

Traded: Nov 17, 2026. Filed: Nov 18, 2026. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Bolt Biotherapeutics recently?

For Bolt Biotherapeutics, OQRO holds 12 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the BOLT page.

Does this mean BOLT stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Bolt Biotherapeutics

Everything OQRO holds on this company is on its BOLT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data